Optimizing Reperfusion to Improve Outcomes and Neurologic Function
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 740 participants.
Also called NCT06990867
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 740 participants
- Sponsor
- Registry
-
NCT06990867
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Belgium, Bulgaria, Canada, China, France, Germany, Greece, Hungary, Italy, Japan, Latvia, Lithuania, Malaysia, Portugal, Serbia, South Korea, Spain, Thailand, United Kingdom, Vietnam
- Registry status
- Recruiting
Technical summary
Registry record NCT06990867. Randomized; quadruple masking; primary purpose treatment. Start 2025-05-15 (actual); primary completion 2029-10-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Optimizing Reperfusion to Improve Outcomes and Neurologic Function
- Acronym
- ORION
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- JX10
- Intervention (Drug)
- Placebo
- Lead sponsor
- Corxel Pharmaceuticals
Record details
- Record id
cardio:ct-nct06990867- Content hash
5370e6ec1da999c435c7b01b32e9df6f4d02dc3a5419090a7651305259b5bde9